Data regarding the toxicity of brolucizumab is not readily available.L9089
Brolucizumab, also known as RTH258 or ESBA1008,A187211 is a monoclonal antibody indicated to treat neovascular age related macular degeneration.L9089
Brolucizumab was granted FDA approval in October 2019.L9089
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Brolucizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Brolucizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Brolucizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Brolucizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Brolucizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Brolucizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Brolucizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Brolucizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Brolucizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Brolucizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Brolucizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Brolucizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Brolucizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Brolucizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Brolucizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Brolucizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Brolucizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Brolucizumab. |
| Equol | Equol may increase the thrombogenic activities of Brolucizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Brolucizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Brolucizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Brolucizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Brolucizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Brolucizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Brolucizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Brolucizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Brolucizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Brolucizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Brolucizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Brolucizumab. |
| Pamidronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Pamidronic acid. |
| Zoledronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Alendronic acid. |
| Ibandronate | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Ibandronate. |
| Clodronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Etidronic acid. |
| Tiludronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Tiludronic acid. |
| Incadronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Incadronic acid. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Brolucizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brolucizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Brolucizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Brolucizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Brolucizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brolucizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brolucizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Brolucizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Brolucizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Brolucizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Brolucizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Brolucizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brolucizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brolucizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Brolucizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brolucizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brolucizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Brolucizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brolucizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Brolucizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Brolucizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Brolucizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brolucizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brolucizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Brolucizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Brolucizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Brolucizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Brolucizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Brolucizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Brolucizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Brolucizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Brolucizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Brolucizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Brolucizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Brolucizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Brolucizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Brolucizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Brolucizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Brolucizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Brolucizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Brolucizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Brolucizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Brolucizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Brolucizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Brolucizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Brolucizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Brolucizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Brolucizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Brolucizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Brolucizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Brolucizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Brolucizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Brolucizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Brolucizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Brolucizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Brolucizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Brolucizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Brolucizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Brolucizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Brolucizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Brolucizumab. |